Tarride, J.-É.
Adachi, J. D.
Brown, J. P.
Schemitsch, E.
Slatkovska, L.
Burke, N.
Funding for this research was provided by:
Amgen Canada
Article History
Received: 15 October 2020
Accepted: 4 February 2021
First Online: 18 February 2021
Declarations
:
: This retrospective study made use of de-identified aggregate-level data that was obtained from the ICES data repository following patient-level analysis. The study protocol was approved by the Advarra Institutional Review Board.
: For this type of study, formal consent is not required.
: All authors approved the final version and agree to be accountable for all aspects of the work.
: JET has received consulting fees, research funding, and honoraria from Allergan, AstraZeneca, Amgen, CSL Behring, Janssen, Novo Nordisk, Sage, Assurex/Myriad, Edwards Lifesciences, Pfizer, Roche, Merck, GlaxoSmithKline, Evidera, PCDI, and CADTH. JDA has received consulting fees from Amgen and Eli Lilly; received research funding from Amgen, Radius, Pfizer, and BMS; served on the speakers’ bureau for Amgen; and served on boards for the International Osteoporosis Foundation and Ontario Rheumatology Association. JPB has received consulting fees and honoraria from Amgen and Servier; received research funding from Mereo BioPharma, Radius Health, and Servier; and served on speakers’ bureau for Amgen. ES has received consulting fees from Amgen. LS is an employee of and owns stock in Amgen. NB is an employee of Amgen. Medical writing support was provided by Amaris Consulting and funded by Amgen Canada Inc.
: The opinions, results, and conclusions reported are those of the authors. No endorsement by ICES or any of its funders or partners is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions, and statements expressed herein are those of the author, and not necessarily those of CIHI.